Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREBAD study of oral 6-bromotryptophan in new-onset type 1 diabetes
NL-OMON58422Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing 6-bromotryptophan with Placebo (2 arms). Primary endpoints: Beta-cell function by mixed-meal tolerance test, Urinary C-peptide/creatinine and 4 more. Started Apr 2026; status: recruiting.
02
Drugs
6-bromotryptophan
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON58422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58422.